- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07632378
The Effect of taVNS and Upper GI Motility
The Effect of Non-invasive Transauricular Vagus Nerve Stimulation on Upper Gastrointestinal Motility in Healthy Individuals
This single-center randomized controlled cross-over trial aims to investigate the effect of transcutaneous auricular vagus nerve stimulation on upper gastrointestinal motility in healthy individuals.
The primary aim of this study is to assess the impact of tVNS on gut motor function, with regards to its potential to induce phase III contractions in the upper GI tract.
Secondary objectives include:
- To study the effect of tVNS on other parameters characterizing upper GI motility such as the number of duodenal phase III contractions, gastric and duodenal phase MMCs, amplitude of antral contractions and motility index
- To study the effect of tVNS on plasma levels of motilin and PP
- To evaluate the effect of tVNS on parameters related to autonomic outflow, using a Shimmer3 GSR Sensor for heart rate variability and skin conductance.
- To compare the results of the measurements of antroduodenal manometry with measurements of Gastric Alimetry
Participants will undergo tVNS (applied to the cymba conchae of the left ear) alternating with sham stimulation (using a non-conducting electrode) in a blinded, pre-randomized fashion, using two 4-hour blocks during an 8-hour fasted antroduodenal manometry recording period. Optionally, participants may simultaneously also undergo body surface gastric mapping using the Gastric Alimetry system.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Visit 1 (screening visit) Following written informed consent, the medical history of each subject will be checked during a structured interview. A pregnancy will be excluded by a urine test (due to the use or fluoroscopy during insertion of the manometry catheter) and a 12-lead ECG will be performed at the end of the screening visit. The rationale for this is to ensure no evidence of cardiac conduction disorders and an additional safety step to ensure no cardiac dysrhythmic affect with tVNS use. All information obtained during the screening visit will be recorded in using an electronic CRF provided by Castor EDC, provided by the Clinical Trial Centre Maastricht (CTCM).
Visit 2 (test day) Participants will arrive after an overnight fast at the GI physiology unit of the Maastricht University Medical Center, where a trained and experienced nurse will insert an antroduodenal manometry catheter through the nose into the duodenum under fluoroscopy control and supervision of a gastroenterologist (as per routine clinical procedure). Using this catheter, stomach and duodenum motility patterns will be recorded for 8 hours. After the manometry is inserted, the tVNS device will be connected with an electrode which delivers stimulation transcutaneous in the outer ear. Participants will receive two types of stimulation (i.e. tVNS vs sham) in 2 blocks of 4 hours during the 8-hour registration period. The order of stimulation applied is randomized. Gastric phase III contractions generally occur every 90 minutes, so the 4-hour period is considered sufficient to detect two phase III contractions considered sufficient to detect the two phase III contractions.(10)
An iv catheter will be inserted to draw blood during the 8-hour registration period. Blood samples, each witch a maximum volume of 10 mL, will be taken every 30 minutes to measure motilin and PP as surrogate markers of vagal efferent influence on GI motor function. In addition, autonomic parameters will be registered during the entire test period, using a Shimmer3 GSR sensor. After the 8-hour test period, the manometry catheter, the electrodes of the tVNS device and the iv cannula are removed.
Additionally, participants may opt to take part in a body surface gastric mapping assessment. This non-invasive, electrophysiological measurement is performed using the Gastric Alimetry system, which involves placing a large adhesive patch with multiple electrodes on the upper abdomen. The system records gastric myoelectrical activity over time, providing insight into gastric motility patterns. The measurement is conducted concurrently with the manometry registration period.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Kimberly Hawinkels, MD
- Numero di telefono: +31883887808
- Email: kimberly.hawinkels@maastrichtuniversity.nl
Luoghi di studio
-
-
Limburg
-
Maastricht, Limburg, Olanda, 6229ER
- Reclutamento
- Maastricht University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Healthy participants (defined as those without a pre-existing medical comorbidity, including those without a history of cardiac arrhythmia).
- Age between 18 and 55 years.
- Ability to understand and speak the Dutch language.
Exclusion Criteria:
- Pregnancy or lactation.
- Use of any substances (such as medication or recreational drugs) influencing gastrointestinal motility
- Not meeting the inclusion criteria above.
- Students and employees of Maastricht University are not precluded from participation, unless they have a direct personal, professional of hierarchical position with regards to any of the study team members or their department.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Transcutaneous Auricular Vagal Nerve Stimulation
TaVNS
|
taVNS will be provided during a 4-hour block of the 8-hour fasted antroduodenal manometry recording period.
|
|
Comparatore placebo: Sham stimulation
Sham stimulation with a non-conducting electrode
|
Sham stimulation will be provided during a 4-hour block of the 8-hour fasted antroduodenal manometry recording period.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
A clinically meaningful increase in phase III contractions
Lasso di tempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
|
A clinically meaningful increase in the number of phase III contractions of antral origin in the fasted period during the tVNS stimulation compared to the sham stimulation.
|
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
A clinically relevant increase in other upper GI motility parameters
Lasso di tempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
|
A clinically relevant increase in other parameters characterizing upper GI motility such as the number of duodenal phase III contractions, gastric and duodenal phase MMCs, amplitude of antral contractions and motility index
|
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
|
|
Concentration of plasma motilin and pancreatic polypeptide
Lasso di tempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
|
Changes in plasma motilin and pancreatic polypeptide following taVNS vs. sham stimulation
|
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
|
|
Autonomic response: heart rate variability
Lasso di tempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
|
Changes in heart rate variability measured continuously using a Shimmer3 GSR sensor
|
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
|
|
Electrodermal response: skin conductance
Lasso di tempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
|
Changes in skin conductance following taVNS vs sham stimulation, assessed continuously using a Shimmer3 GSR sensor.
|
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
|
|
Agreement between gastric motility measurements obtained by antroduodenal manometry and Gastric Alimetry
Lasso di tempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
|
Agreement between antroduodenal manometry and Gastric Alimetry measurements obtained simultaneously.
|
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Daniel Keszthelyi, MD, PhD, Maastricht University Medical Center
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- NL86446.068.24
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Vagal Nerve Stimulation
-
University of British ColumbiaCompletatoStimolazione cerebrale profonda | Disfonia spasmodica | Distonia laringeaCanada
-
The Second Hospital of TangshanChinese PLA General HospitalCompletatoPerdita di tessuto molle con difetto del nervo
-
Insel Gruppe AG, University Hospital BernReclutamentoMetastasi al cervelloSvizzera
-
Axogen CorporationAttivo, non reclutanteSindrome del tunnel cubitale ricorrente | Sindrome del tunnel cubitale recalcitranteStati Uniti
-
Henry Ford Health SystemSospesoComplicanze postoperatorie | Cancro testa e collo | Dissezione del colloStati Uniti
-
University of Sao PauloSconosciutoDisordine depressivo | Disordine bipolare | Episodio depressivoBrasile
-
AtriCure, Inc.ReclutamentoDolore post operatorioStati Uniti, Belgio, Austria, Germania, Regno Unito
-
University Hospital TuebingenCompletatoGrave depressioneGermania
-
Jung-Sun LeeSeoul St. Mary's Hospital, The Catholic University; Seoul National University... e altri collaboratoriNon ancora reclutamentoDisturbo depressivo maggiore (MDD) | Depressione - Disturbo depressivo maggioreCorea del Sud
-
Kaohsiung Medical University Chung-Ho Memorial...SconosciutoChirurgia della tiroide | Nervo laringeo ricorrente | Monitoraggio elettromiograficoTaiwan